{
  "id": "58a6d89660087bc10a00002b",
  "type": "yesno",
  "question": "Could plasmepsins be used as targets for developing anti-malaria drugs?",
  "ideal_answer": "Yes, plasmepsins, which are essential Plasmodium proteases, could be highly promising anti-malarial drug targets.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/12767832",
    "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
    "http://www.ncbi.nlm.nih.gov/pubmed/21334328",
    "http://www.ncbi.nlm.nih.gov/pubmed/26214367",
    "http://www.ncbi.nlm.nih.gov/pubmed/18442137",
    "http://www.ncbi.nlm.nih.gov/pubmed/17727268",
    "http://www.ncbi.nlm.nih.gov/pubmed/16838300",
    "http://www.ncbi.nlm.nih.gov/pubmed/15181345",
    "http://www.ncbi.nlm.nih.gov/pubmed/19472268",
    "http://www.ncbi.nlm.nih.gov/pubmed/21136953",
    "http://www.ncbi.nlm.nih.gov/pubmed/14636976",
    "http://www.ncbi.nlm.nih.gov/pubmed/8816746",
    "http://www.ncbi.nlm.nih.gov/pubmed/11841219",
    "http://www.ncbi.nlm.nih.gov/pubmed/24975562",
    "http://www.ncbi.nlm.nih.gov/pubmed/23466235",
    "http://www.ncbi.nlm.nih.gov/pubmed/16054370",
    "http://www.ncbi.nlm.nih.gov/pubmed/12435452",
    "http://www.ncbi.nlm.nih.gov/pubmed/16138859",
    "http://www.ncbi.nlm.nih.gov/pubmed/25719272",
    "http://www.ncbi.nlm.nih.gov/pubmed/22242846",
    "http://www.ncbi.nlm.nih.gov/pubmed/21382523",
    "http://www.ncbi.nlm.nih.gov/pubmed/27718413",
    "http://www.ncbi.nlm.nih.gov/pubmed/24468190",
    "http://www.ncbi.nlm.nih.gov/pubmed/26566224",
    "http://www.ncbi.nlm.nih.gov/pubmed/19437467",
    "http://www.ncbi.nlm.nih.gov/pubmed/9561244",
    "http://www.ncbi.nlm.nih.gov/pubmed/21760810",
    "http://www.ncbi.nlm.nih.gov/pubmed/17585371",
    "http://www.ncbi.nlm.nih.gov/pubmed/24983235",
    "http://www.ncbi.nlm.nih.gov/pubmed/20056606",
    "http://www.ncbi.nlm.nih.gov/pubmed/21428877",
    "http://www.ncbi.nlm.nih.gov/pubmed/15011947"
  ],
  "snippets": [
    {
      "text": "Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25719272",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Given that the parasite needs the resulting amino acid building blocks for its growth and development, plasmepsins are an important antimalarial drug target. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25719272",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Due to early crystallographic evidence, plasmepsin II (Plm II) emerged as well explored target to develop novel antimalarials as well as a starting point to develop inhibitors targeting some other subtypes of plasmepsins i.e. Plm I, II, IV and V. With the advancements in drug discovery, several computational and synthetic approaches were employed in order to develop novel inhibitors targeting Plm II. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Plasmepsin V, an essential aspartyl protease of malaria parasites, has a key role in the export of effector proteins to parasite-infected erythrocytes. Consequently, it is an important drug target for the two most virulent malaria parasites of humans, Plasmodium falciparum and Plasmodium vivax.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Plasmepsin V (PmV) is an essential Plasmodium protease and a highly promising antimalarial target, which still lacks molecular characterization and drug-like inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our inhibitors act 'on-target', confirmed by cellular interference of PmV function and biochemical interaction with inhibitors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our work disclosed novel pursuable drug design strategies for highly efficient PmV inhibition highlighting novel molecular elements necessary for picomolar activity against PmV. All the presented data are discussed in respect to human aspartic proteases and previously reported inhibitors, highlighting differences and proposing new strategies for drug development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "High binding likeness on antimalarial target plasmepsin was detected through molecular docking. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24975562",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This provides the first direct evidence that PMV activity is essential for protein export in Plasmodium spp. and for parasite survival in human erythrocytes and validates PMV as an antimalarial drug target.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983235",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The export mechanism involves the Plasmodium export element (PEXEL), which is a cleavage site for the parasite protease, Plasmepsin V (PMV). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983235",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Plasmepsin II (PM II) is an attractive target for anti-malaria drug discovery, which involves in host hemoglobin degradation in the acidic food vacuole.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466235",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These methods are utilized to search for inhibitors of the aspartyl proteases, plasmepsin II and cathepsin D. Plasmepsin II, a protease found in the malaria parasite, hydrolyzes human hemoglobin, the nutrient source for the parasite and is a new target for anti-malaria therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9561244",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Given recent advances in understanding the fundamental roles of the various plasmepsins, it is likely that the most effective antimalarial plasmepsin targets will be the non-digestive vacuole plasmepsins.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242846",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Plasmepsins (PMs) are essential proteases of the plasmodia parasites and are therefore promising targets for developing drugs against malaria.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19472268",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore, the plasmepsins of malaria parasites have been recognized as attractive antimalarial drug targets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21334328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "As inhibition of plasmepsins leads to the parasite's death, these enzymes can be utilized as potential drug targets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16138859",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "falciparum plasmepsins II and IV make structure-based drug design of antimalarial compounds that focus on inhibiting plasmepsins possible.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18442137",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The malarial parasite encodes two homologous aspartic proteases, plasmepsins I and II, which are essential components of its hemoglobin-degradation pathway and are novel targets for antimalarial drug development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8816746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "vivax plasmepsins (PvPMs) from different geographical regions are of utmost importance for drugs and vaccine designs for anti-malarial strategies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In P.falciparum, plasmepsins I, II, IV and HAP have been directly implicated in hemoglobin degradation during malaria infection, and are now considered targets for anti-malarial drug design.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12767832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results shed light on the role of V105 and T108 residues in plasmepsin specificities, and they should be useful in structure-based design of novel, selective inhibitors that may serve as antimalarial drugs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18442137",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The aspartic proteases plasmepsins, whose inhibition leads to parasite death, are classified as targets for the design of potent drugs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21760810",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A large compound library of about 1 million chemical compounds was docked on 5 different targets of plasmepsins using two different docking software, namely FlexX and AutoDock.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17727268",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Plasmodium aspartic proteases known as plasmepsins play an important role on haemoglobin degradation and are being studied as drug targets for chemotherapy of malaria.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636976",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our study revealed about 100 parasite-coded gene products that included many known drug targets such as Pf hypoxanthine guanine phosphoribosyl transferase, Pf L-lactate dehydrogenase, and Plasmepsins.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136953",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The two aspartic proteases, plasmepsins I and II, from Plasmodium falciparum have recently emerged as potential targets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16054370",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Plasmepsins are highly promising as drug targets, especially when combined with the inhibition of falcipains that are also involved in hemoglobin catabolism.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17585371",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Among such enzymes, Plasmepsins (aspartic proteases) and, especially, Falcipains (cysteine proteases) are highly promising antimalarial drug targets.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21428877",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The high sequence conservations between the plasmepsins from the isolates support the notion that the enzymes could be reliable targets for new antimalarial chemotherapeutics.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15181345",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Due to early crystallographic evidence, plasmepsin II (Plm II) emerged as well explored target to develop novel antimalarials as well as a starting point to develop inhibitors targeting some other subtypes of plasmepsins i.e.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Plasmepsin, an aspartic protease, which is involved in the hemoglobin breakdown into smaller peptides emerged as a crucial target to develop new chemical entities to counter malaria.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "were employed in order to develop new chemical entities targeting Plm II.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With the advancements in drug discovery, several computational and synthetic approaches were employed in order to develop novel inhibitors targeting Plm II.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "vivax plasmepsins (PvPMs) from different geographical regions are of utmost importance for drugs and vaccine designs for anti-malarial strategies..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We developed a potent inhibitor of plasmepsin V, called WEHI-842, which directly mimics the Plasmodium export element (PEXEL).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In order to validate appropriate use of PM4 as potential anti-malarial drug target, studies on genetic and structural variations among P.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Over the past decade, much effort has been placed towards developing plasmepsin inhibitors as antimalarial agents, particularly targeting the digestive vacuole.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242846",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000962",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015195",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016780",
    "http://www.disease-ontology.org/api/metadata/DOID:12365",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008288"
  ],
  "exact_answer": "Yes"
}